7.34
                                            Schlusskurs vom Vortag:
              $7.25
            Offen:
              $7.28
            24-Stunden-Volumen:
                701.10K
            Relative Volume:
              0.17
            Marktkapitalisierung:
                $1.54B
            Einnahmen:
              $557.51M
            Nettoeinkommen (Verlust:
              $-35.71M
            KGV:
              -40.78
            EPS:
                -0.18
            Netto-Cashflow:
                $15.50M
            1W Leistung:
              +2.03%
            1M Leistung:
              -3.21%
            6M Leistung:
                -16.99%
            1J Leistung:
              -8.29%
            Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
                  
                      Biocryst Pharmaceuticals Inc
                    
                Sektor
                  Telefon
                  
                      919-859-1302
                    
                Adresse
                  
                      4505 EMPEROR BOULEVARD, DURHAM, NC
                    
                Vergleichen Sie BCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV | 
|---|---|---|---|---|---|---|
|   
                          
                                BCRX
                            
                             Biocryst Pharmaceuticals Inc | 7.34 | 1.53B | 557.51M | -35.71M | 15.50M | -0.18 | 
|   
                          
                                ZTS
                            
                             Zoetis Inc | 142.98 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 | 
|   
                          
                                TAK
                            
                             Takeda Pharmaceutical Co Adr | 13.46 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 | 
|   
                          
                                HLN
                            
                             Haleon Plc Adr | 9.2282 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 | 
|   
                          
                                TEVA
                            
                             Teva Pharmaceutical Industries Ltd Adr | 20.09 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 | 
|   
                          
                                UTHR
                            
                             United Therapeutics Corp | 448.00 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 | 
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung | 
|---|---|---|---|
| 2025-10-15 | Fortgesetzt | TD Cowen | Buy | 
| 2025-10-01 | Herabstufung | Evercore ISI | Outperform → In-line | 
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight | 
| 2025-02-25 | Eingeleitet | Wedbush | Outperform | 
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight | 
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform | 
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy | 
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy | 
| 2023-02-22 | Hochstufung | Needham | Hold → Buy | 
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform | 
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line | 
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform | 
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight | 
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral | 
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform | 
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold | 
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight | 
| 2021-03-01 | Eingeleitet | Cowen | Outperform | 
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight | 
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral | 
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight | 
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy | 
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform | 
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight | 
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight | 
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral | 
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral | 
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform | 
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight | 
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform | 
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight | 
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy | 
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy | 
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight | 
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform | 
| 2016-02-09 | Bestätigt | FBR Capital | Outperform | 
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral | 
| 2016-02-09 | Herabstufung | Needham | Buy → Hold | 
                    Alle ansehen
                     
                  
                Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
Will BioCryst Pharmaceuticals Inc. stock maintain growth storyGlobal Markets & Reliable Intraday Trade Plans - newser.com
Is BioCryst Pharmaceuticals Inc. stock bottoming out2025 Momentum Check & Smart Swing Trading Techniques - newser.com
Is BioCryst Pharmaceuticals Inc. stock ready for a breakoutEarnings Risk Summary & Real-Time Price Movement Reports - newser.com
What technical models suggest about BioCryst Pharmaceuticals Inc.’s comebackJuly 2025 Trade Ideas & Smart Money Movement Alerts - newser.com
Why retail investors pile into BioCryst Pharmaceuticals Inc. stock2025 Short Interest & Verified Technical Signals - newser.com
Will BioCryst Pharmaceuticals Inc. stock attract ESG investorsMarket Sentiment Summary & Fast Exit/Entry Strategy Plans - newser.com
Why BioCryst Pharmaceuticals Inc. stock could benefit from AI revolutionWeekly Stock Recap & Reliable Intraday Trade Alerts - newser.com
# BioCryst’s SWOT analysis: stock positioned for growth amid HAE market expansion - Investing.com
BioCryst Pharmaceuticals (BCRX) Price Target Increased by 19.59% to 21.51 - Nasdaq
BioCryst Pharmaceuticals Inc.’s volatility index tracking explainedJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com
Why BioCryst Shares Plunged - AOL.com
Aug Shorts: Why hedge funds are buying BioCryst Pharmaceuticals Inc. stockTrade Entry Report & Weekly Stock Performance Updates - Fundação Cultural do Pará
When is the best time to exit BioCryst Pharmaceuticals Inc.July 2025 Snapshot & Free Low Drawdown Momentum Trade Ideas - newser.com
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? - sharewise.com
Will BioCryst Pharmaceuticals Inc. stock outperform international peersPortfolio Update Report & AI Optimized Trading Strategy Guides - Fundação Cultural do Pará
BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Monday - MarketBeat
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
        In Yahoo öffnen
        |
        In Google öffnen
            |
            In Finviz öffnen
        |
        In MarketWatch öffnen
            |
            Öffnen Sie in EDGAR    
        |
        Offen in Reuters
    
    
                Kapitalisierung:
                 
                  | 
                Volumen (24h):
                 
            
         
                     
                             Holen Sie sich die Stockscreener-App
                    Holen Sie sich die Stockscreener-App